Open AccessThe potential of induced pluripotent stem cells for discriminating neurodevelopmental disorders
Author(s) -
Stock Ricarda,
Jeckel Pauline,
Kraushaar Udo,
Wüst Richard,
Fallgatter Andreas,
Volkmer Hansjürgen
Publication year - 2021
Publication title -
stem cells translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.781
H-Index - 71
eISSN - 2157-6580
pISSN - 2157-6564
DOI - 10.1002/sctm.20-0206
Subject(s) - induced pluripotent stem cell , autism , neuroscience , disease , schizophrenia (object oriented programming) , autism spectrum disorder , drug discovery , biology , human induced pluripotent stem cells , transcriptome , computational biology , bioinformatics , embryonic stem cell , medicine , genetics , psychiatry , gene , pathology , gene expression
Studying human disease‐specific processes and mechanisms in vitro is limited by a lack of valid human test systems. Induced pluripotent stem cells (iPSCs) evolve as an important and promising tool to better understand the molecular pathology of neurodevelopmental disorders. Patient‐derived iPSCs enable analysis of unique disease mechanisms and may also serve for preclinical drug development. Here, we review the current knowledge on iPSC models for schizophrenia and autism spectrum disorders with emphasis on the discrimination between them. It appears that transcriptomic analyses and functional read‐outs are the most promising approaches to uncover specific disease mechanisms in vitro.